Cover later at higher price for sure! See you at $35/share by year end.
JPMorgan Analysts Kasimov, Fye and Rama will host a conference call with CEO Clay Siegall on June 12 at 11 am.
It sounds great on the business sense to me that SGEN will now have access to the CAR-T/TCR/TIL technology to fight cancer. It may be a combination of ADC/CAR-T techology cancer therapy.
Please share with us your insight into this collaboration.